New Therapies Show Promise for Autoimmune Diseases Affecting Muscles, Skin, and Heart

Recent research at the University Hospital Düsseldorf in Germany is exploring innovative treatment approaches for severe autoimmune diseases, specifically anti-Jo1+ antisynthetase syndrome (ASyS) and diffuse cutaneous systemic sclerosis (dcSSc). These conditions, often characterized by muscle weakness, skin fibrosis, and heart involvement, have proven challenging to treat, with many patients failing to respond to conventional therapies. Compassionate use programs involving blinatumomab and teclistamab, followed by rituximab maintenance therapy, are showing encouraging results in a subset of critically ill patients.

Understanding ASyS and dcSSc

Anti-Jo1+ antisynthetase syndrome (ASyS) is a rare autoimmune disease typically marked by the presence of anti-Jo1 antibodies. Symptoms often include muscle weakness, interstitial lung disease (ILD), and mechanic’s hands (skin changes on the fingers). Patients frequently experience flares despite treatment with immunosuppressants like methotrexate, azathioprine, and rituximab.

Diffuse cutaneous systemic sclerosis (dcSSc) is a chronic autoimmune disease affecting the connective tissues, skin, and internal organs. It’s characterized by widespread skin thickening and can lead to complications affecting the lungs, heart, and kidneys. Patients with dcSSc often exhibit autoantibodies, such as those against topoisomerase 1 or fibrillarin.

Challenges in Treatment and the Need for New Approaches

Patients included in the study had previously failed multiple treatments, highlighting the difficulty in managing these conditions. All patients with ASyS were positive for anti-Jo1 autoantibodies, and most had not responded to at least four prior immunomodulatory medications, including rituximab (RTX). Similarly, all patients with dcSSc had widespread skin fibrosis, ILD, and primary heart involvement, and had previously failed at least three different immunomodulatory/antifibrotic drugs.

Blinatumomab and Teclistamab: Targeted Therapies

Blinatumomab and teclistamab are bispecific T-cell engagers (TCEs) designed to target and eliminate B cells, a type of immune cell involved in the autoimmune response. These therapies were administered through compassionate use programs, reserved for patients with severe, life-threatening conditions who had exhausted other treatment options.

• Blinatumomab was administered via continuous intravenous infusion over a period of 14 days, leading to rapid B cell depletion.
• Teclistamab was administered subcutaneously, with potential for extended intervals between doses, also resulting in significant B cell depletion.

To prevent the re-emergence of B cells, patients received maintenance therapy with rituximab (RTX) following the TCE treatment. The RTX dosing schedule was adjusted based on individual patient responses and the pharmacokinetics of the TCE.

Clinical Observations and Outcomes

The study involved five patients with ASyS and five patients with dcSSc. While the full extent of the long-term effects is still being evaluated, initial observations suggest potential benefits:

• Patients with ASyS experienced varying degrees of improvement in muscle weakness, ILD, and skin manifestations.
• Patients with dcSSc showed improvements in skin fibrosis, ILD, and cardiac involvement.
• In some cases, patients experienced a reduction in autoantibody levels and improvements in pulmonary function.

However, the therapies were not without side effects. Patients received infection prophylaxis (aciclovir and cotrimoxazole) and intravenous immunoglobulin (IVIG) to manage potential complications.

Further Research and Future Directions

This research represents a promising step forward in the treatment of severe ASyS and dcSSc. Further studies are needed to confirm these findings, optimize treatment protocols, and identify biomarkers that can predict treatment response. The compassionate use of blinatumomab and teclistamab, combined with rituximab maintenance therapy, offers a potential new avenue for managing these challenging autoimmune diseases.

Disclaimer

This article is based on research conducted at the University Hospital Düsseldorf as of February 2026. The information provided is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.